Oslo University Hospital / Oslo Universitetssykehus Rikshospitalet

Hospital


Location: Oslo, Norway (NO) NO

ISNI: 0000000403898485

ROR: https://ror.org/00j9c2840

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Erratum to: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Nature Communications, (2018), 9, 1, (3707), 10.1038/s41467-018-04989-w) (2019) Went M, Sud A, Foersti A, Halvarsson BM, Weinhold N, Kimber S, Van Duin M, et al. Journal article, Erratum IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling (2019) Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, Greene S, et al. Journal article GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways (2019) López-Isac E, Acosta-Herrera M, Kerick M, Assassi S, Satpathy AT, Granja J, Mumbach MR, et al. Journal article Autotaxin activity predicts transplant-free survival in primary sclerosing cholangitis (2019) Dhillon AK, Kremer A, Kummen M, Boberg KM, Elferink RP, Karlsen TH, Beuers U, et al. Journal article Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course (2019) Cavagna L, Trallero-Araguas E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, et al. Journal article Imaging in ESC clinical guidelines: chronic coronary syndromes (2019) Saraste A, Barbato E, Capodanno D, Edvardsen T, Prescott E, Achenbach S, Bax JJ, et al. Journal article Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease by Use of Mycophenolate at Baseline: Subgroup Analysis of the SENSCIS Trial (2019) Highland K, Distler O, Kuwana M, Allanore Y, Assassi S, Azuma A, Bourdin A, et al. Conference contribution The INBUILD Trial of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Diseases: Subgroup with Autoimmune Diseases (2019) Matteson E, Kelly C, Distler J, Mann-Vold AMH, Seibold J, Mittoo S, Distler O, et al. Conference contribution Delineating the clinical spectrum due to heterozygous TRAF7 missense mutations: A series of 38 cases (2019) Amiel J, Mishra K, Castilla L, Selmer KK, Barak T, Yang S, Blanco-Sanchez B, et al. Conference contribution Consensus statements and recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 11-13 November 2018 (2019) Ahmed N, Audebert H, Turc G, Cordonnier C, Christensen H, Sacco S, Sandset EC, et al. Journal article